Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
Ana Cristina de Medeiros Ribeiro, Nádia Emi Aikawa, Carla Gonçalves Schahin Saad, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1744-1751
Open Access | Times Cited: 175

Showing 51-75 of 175 citing articles:

Immunogenicity of COVID-19 adsorbed inactivated vaccine (CoronaVac) and additional doses of mRNA BNT162b2 vaccine in immunocompromised adults compared with immunocompetent persons
Karim Yaqub Ibrahim, R. Moreira, C. Santos, et al.
Revista do Instituto de Medicina Tropical de São Paulo (2024)
Open Access | Times Cited: 3
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Yandi Zhang, Jo‐Lewis Banga Ndzouboukou, Mengze Gan, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 24
Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis
Georgina Nakafero, Matthew J. Grainge, Tim Card, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 4, pp. 1445-1450
Open Access | Times Cited: 17
Immunogenicity and safety of an inactivated SARS‐CoV‐2 vaccine in people living with HIV: A cross‐sectional study
Shaohang Cai, Guichan Liao, Tao Yu, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 9, pp. 4224-4233
Open Access | Times Cited: 16
Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes
Xiaoying Zhou, Huixia Lu, Miaomiao Sang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 9
Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination
Ana Eliza Garcia Ralise, Taís Mendes Camargo, Fernando Augusto Lima Marson
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 9
Erythrocyte-enabled immunomodulation for vaccine delivery
Fei Wang, Rongling Zong, Gang Chen
Journal of Controlled Release (2021) Vol. 341, pp. 314-328
Closed Access | Times Cited: 22
Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
Bruno Gualano, Ítalo Ribeiro Lemes, Rafael Pires da Silva, et al.
Brain Behavior and Immunity (2021) Vol. 101, pp. 49-56
Open Access | Times Cited: 20
COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey
Leonardo Santos Hoff, R Naveen, Samuel Katsuyuki Shinjo, et al.
Rheumatology International (2022) Vol. 43, Iss. 1, pp. 47-58
Open Access | Times Cited: 15
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
Flávio Signorelli, Gustavo Guimarães Moreira Balbi, Nádia Emi Aikawa, et al.
Lupus (2022) Vol. 31, Iss. 8, pp. 974-984
Open Access | Times Cited: 14
Immunogenicity and Safety of SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases: A Systematic Review and Meta-analysis
Akhil Sood, Minh Tâm Tran, V. Rama Murthy, et al.
JCR Journal of Clinical Rheumatology (2022) Vol. 28, Iss. 8, pp. 381-389
Closed Access | Times Cited: 14
Acquired Thrombotic Thrombocytopenic Purpura Following Inactivated COVID-19 Vaccines: Two Case Reports and a Short Literature Review
Imen Ben Saida, Iyed Maatouk, Radhouane Toumi, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1012-1012
Open Access | Times Cited: 14
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
Daniel Leung, Xiaofeng Mu, Jaime S. Rosa Duque, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Yue Yat Harrison Cheung, Eric H. Y. Lau, Guosheng Yin, et al.
Emerging infectious diseases (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 8
Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
Samuel Katsuyuki Shinjo, Fernando Henrique Carlos de Souza, Isabela Bruna Pires Borges, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 8, pp. 3351-3361
Open Access | Times Cited: 19
Effects of inactivated SARS‐CoV‐2 vaccination on male fertility: A retrospective cohort study
Yehao Dong, Xiaoyun Li, Zewu Li, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Closed Access | Times Cited: 13
Inactivated SARS-CoV-2 vaccine in primary Sjögren’s syndrome: humoral response, safety, and effects on disease activity
Sandra Gofinet Pasoto, Ari Stiel Radu Halpern, Lissiane Karine Noronha Guedes, et al.
Clinical Rheumatology (2022) Vol. 41, Iss. 7, pp. 2079-2089
Open Access | Times Cited: 12
Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis
Maxime Auroux, Benjamin Laurent, Baptiste Coste, et al.
Joint Bone Spine (2022) Vol. 89, Iss. 5, pp. 105380-105380
Open Access | Times Cited: 12
Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
Carla Gonçalves Schahin Saad, Matheus S.R. Silva, Perceval D. Sampaio-Barros, et al.
Joint Bone Spine (2022) Vol. 90, Iss. 1, pp. 105464-105464
Open Access | Times Cited: 12
Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
Hangjie Zhang, Qianhui Hua, Nani Xu, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 7
Intraocular inflammation following COVID-19 vaccination: the clinical presentations
Sophia Li, Mary Ho, Andrew C. Y. Mak, et al.
International Ophthalmology (2023) Vol. 43, Iss. 8, pp. 2971-2981
Open Access | Times Cited: 7
Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
Chutima Seree-aphinan, Kumutnart Chanprapaph, Ploysyne Rattanakaemakorn, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 17
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
Б. С. Белов, А. М. Лила, Е. Л. Насонов
Rheumatology Science and Practice (2022) Vol. 60, Iss. 1, pp. 21-31
Open Access | Times Cited: 11
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
Yiqing Zheng, Hejun Li, Ling Chen, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines
Sevilay Batıbay, Rezan Koçak Ulucaköy, Zafer Günendi, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 6, pp. 2089-2096
Open Access | Times Cited: 11

Scroll to top